Harnessing the power of Artificial Intelligence to unlock further potential of known drugs for orphan diseases

We leverage the power of Artificial Intelligence to repurpose drugs for orphan diseases

We are a team of talented scientists with a passion for innovation

STANDARD DRUG DISCOVERY AND DEVELOPMENT

$1 to $2 billion
cost of developing a new drug
10 to 15 years
to develop a new drug
90%
of new chemical entities fail before they even reach the clinics

WE CAN REDUCE THOSE NUMBERS TO

$250k to $50M
cost of developing a new drug
4 to 5 years
to develop a new drug

OUR APPROACH

Leveraging the power of Artificial Intelligence

Focused on orphan diseases

Repurposing drugs for new therapeutic indications

Learn about our Unique Approach

PROPRIETARY PIPELINE

7 000

Only 5% have approved treatments

The main focus of our pipeline are Orphan diseases with a high unmet medical need.

Learn about our pipeline

PARTNERSHIP

Workflow adapted to your needs.

Learn how you can work with us

Our business model is a combination of in-house development and external collaborations. We have entered into multiple industry partnerships, as well as academic collaborations

OUR PERFORMANCE INDICATORS

77%
of our starting programs revealed positive hits that were confirmed at the laboratory bench and that were patentable
27%
of those hits are in preclinical or clincial development
20%
of those preclinical or clinical programs have clinical stage Phase 2 positive results

WE COOPERATE WITH

SOM BIOTECH IN THE MEDIA

LATEST NEWS

SOM Biotech announces the completion of recruitment in the Phase IIb study of the treatment of chorea in Huntington’s disease patients with SOM3355

SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligence platform (SOMAIPRO®), is pleased to announce that the recruitment of the Phase IIb clinical study with SOM3355 as a treatment for Huntington’s chorea has been completed.

SOM Biotech announces the election of Silvia Panigone as Executive Chair

Barcelona, Spain, March 26th, 2024. SOM Biotech (SOM), a clinical-stage drug discovery and development company based on a unique and proprietary Artificial Intelligent (AI) platform, appoints Silvia Panigone PhD, MBA as Executive Chair of the Board of SOM.

SOM Biotech closes an internal round for €5.5 Million

Barcelona, Spain. March 12, 2024. SOM Biotech (“SOM” or the “Company”), a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligent (AI) platform, announces the closure of an internal round for € 5.5 million to secure the completion of the Phase IIb study on Huntington patients with its lead candidate SOM3355.…

SOM Biotech at the 10th Drug Discovery Innovation Programme

November 29, 2019

SOM Biotech participated in the 10th Drug Discovery Innovation Programme that took place on November 28th -29th- in Barcelona, Spain. Luca Signorile – Computational Chemist of SOM Biotech –performed the presentation on the topic “Re-Discovering Drugs: Advantages, Perspectives, and the role of AI.” During his speech, he gave an insight into the computational side of…

SOM Biotech at the Clinical Trials Europe 2019 conference

November 27, 2019

SOM Biotech has participated in the “Clinical Trials Europe 2019” conference, that took place on November 19th -21st- in Barcelona, Spain. The “Clinical Trials Europe 2019”, one of the leading platforms to build partnerships to develop clinical trials, attracts a wide range of innovative research centers and business development teams from biotech and pharma companies.…

SOM Biotech at the 10th World Orphan Drug Congress 2019

November 15, 2019

SOM Biotech participated in the World Orphan Drug Congress Europe 2019 on November 12th -14th- in Barcelona, Spain, where the company was a Showcase Sponsor. Raul Insa – CEO of SOM Biotech – presented “Case study: Systematic drug re-innovation and clinical evidence in orphan diseases”. SOM Biotech shared its latest findings in drug discovery and…